The study aims to evaluate the morbidity and mortality outcomes related to dupilumab treatment in patients with cutaneous immune-related adverse events.
Cohort study design
Evaluated patients receiving dupilumab
Assessed morbidity and mortality outcomes
Identified correlations between dupilumab treatment and reduced morbidity
Noted mortality rates associated with treatment outcomes
Found significant improvements in patient quality of life
Abstract
This cohort study evaluates morbidity and mortality outcomes associated with dupilumab treatment in patients with cutaneous immune-related adverse events.